콘텐츠로 건너뛰기
Merck
모든 사진(2)

Key Documents

OP92

Sigma-Aldrich

Anti-BRCA1 (Ab-1) Mouse mAb (MS110)

liquid, clone MS110, Calbiochem®

동의어(들):

Anti-Breast Cancer Susceptibility Protein

로그인조직 및 계약 가격 보기


About This Item

UNSPSC 코드:
12352203
NACRES:
NA.41

생물학적 소스

mouse

Quality Level

항체 형태

purified antibody

항체 생산 유형

primary antibodies

클론

MS110, monoclonal

형태

liquid

포함

≤0.1% sodium azide as preservative

종 반응성

human

제조업체/상표

Calbiochem®

저장 조건

do not freeze

동형

IgG1

배송 상태

wet ice

저장 온도

2-8°C

타겟 번역 후 변형

unmodified

유전자 정보

human ... BRCA1(672)

일반 설명

Anti-BRCA1 (Ab-1), mouse monoclonal, clone MS110, recognizes the ~220 kDa BRCA1 protein in MCF-7 cells. It is validated for WB, IF, IP, and frozen and paraffin sections.
Purified mouse monoclonal antibody generated by immunizing mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells. Recognizes the ~220 kDa BRCA1 protein.
Recognizes the ~220 kDa BRCA1 protein in MCF-7 cells. Does not cross-react with blood group antigens or growth factor receptors such as EGFR. Sold under license of U.S. Patent 5,753,441 and 6,162,897.

면역원

Epitope: within the N-terminal 304 amino acids of BRCA1
Human
recombinant human BRCA1

애플리케이션

Frozen Sections (see application reference)

Immunoblotting (2 µg/ml)

Immunofluorescence (see application reference)

Immunoprecipitation (see application reference)

Paraffin Sections (see application reference)

포장

Please refer to vial label for lot-specific concentration.

경고

Toxicity: Standard Handling (A)

물리적 형태

In 50 mM sodium phosphate buffer, 0.2% gelatin, pH 7.5.

분석 메모

Positive Control
MCF7 cells

기타 정보

Antibody should be titrated for optimal results in individual systems.
Scully, R., et al. 1996. Science272, 123.
Gudas, J.M., et al. 1996. Cell Growth Differ.7, 717.
Vaughn, J.P., et al. 1996. Cell Growth Differ.7, 711.
Goldgar, D.E. and Reilly, P.R. 1995. Nat. Genet.11, 113.
Merajver, S.D., et al. 1995. Clin. Can. Res.1, 539.
Merajver, S.D., et al. 1995. Nat. Genet.9, 439.
Struewing, J.P., et al. 1995. Nat. Genet.11, 198.
Thompson, M.E., et al. 1995. Nat. Genet.9, 444.
Futreal, P.A., et al. 1994. Science266, 120.
Miki, Y., et al. 1994. Science266, 66.
Wilson, C.A., et al. 1999. Nat. Genet.21, 236.

법적 정보

Sold under license of U.S. Patents 5,753,441 and 6,162,897.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

적합한 제품을 찾을 수 없으신가요?  

당사의 제품 선택기 도구.을(를) 시도해 보세요.

Storage Class Code

10 - Combustible liquids

WGK

nwg

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Nerea Matamala et al.
Oncotarget, 7(15), 20068-20079 (2016-03-05)
Emerging evidence suggests that BRCA1 pathway contributes to the behavior of sporadic triple negative breast cancer (TNBC), but little is known about the mechanisms underlying this association. Considering the central role that microRNAs (miRNAs) play in gene expression regulation, the
Aruna Korlimarla et al.
PloS one, 11(4), e0153113-e0153113 (2016-04-15)
Apart from germ-line BRCA1-mutated breast cancers, a significant proportion of women with sporadic triple negative breast cancer (TNBC) sub-type are known to harbour varying levels of BRCA1-dysfuction. There is currently no established diagnostic method to identify these patients. The analysis
Geon Kim et al.
Oncology letters, 17(6), 5023-5029 (2019-06-13)
Breast cancer type 1 susceptibility protein (BRCA1) is a tumor suppressor gene that encodes a nuclear phosphoprotein, which is involved in homologous recombination to repair DNA double strand breaks and maintain genome stability. When BRCA1 is mutated or altered, DNA
Pierre Thouvenot et al.
Journal of cell science, 129(23), 4366-4378 (2016-11-02)
Understanding the effect of an ever-growing number of human variants detected by genome sequencing is a medical challenge. The yeast Saccharomyces cerevisiae model has held attention for its capacity to monitor the functional impact of missense mutations found in human
Young Eun Choi et al.
Oncotarget, 5(9), 2678-2687 (2014-05-07)
The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well to these agents. Combination of PARPis with agents that inhibit

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.